Perspective Therapeutics (CATX) Liabilities and Shareholders Equity (2016 - 2026)
Perspective Therapeutics' Liabilities and Shareholders Equity history spans 16 years, with the latest figure at $410.8 million for Q1 2026.
- On a quarterly basis, Liabilities and Shareholders Equity rose 24.72% to $410.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.3 billion, a 11.35% decrease, with the full-year FY2025 number at $267.0 million, down 21.73% from a year prior.
- Liabilities and Shareholders Equity hit $410.8 million in Q1 2026 for Perspective Therapeutics, up from $267.0 million in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for CATX hit a ceiling of $410.8 million in Q1 2026 and a floor of $58.1 million in Q4 2022.
- Historically, Liabilities and Shareholders Equity has averaged $218.6 million across 5 years, with a median of $267.0 million in 2025.
- Biggest five-year swings in Liabilities and Shareholders Equity: surged 253.93% in 2024 and later dropped 24.63% in 2025.
- Tracing CATX's Liabilities and Shareholders Equity over 5 years: stood at $58.1 million in 2022, then skyrocketed by 68.51% to $97.9 million in 2023, then soared by 248.45% to $341.1 million in 2024, then dropped by 21.73% to $267.0 million in 2025, then soared by 53.86% to $410.8 million in 2026.
- Business Quant data shows Liabilities and Shareholders Equity for CATX at $410.8 million in Q1 2026, $267.0 million in Q4 2025, and $294.8 million in Q3 2025.